Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
By T. Kreisl, L. Kim, Kraig D. Moore, P. Duic, C. Royce, I. Stroud, Nancy Garren, M. Mackey, J. Butman, K. Camphausen and 3 more. Journal of Clinical Oncology, 2009
1,572 citations recorded by the source corpus.
Subfields: Biotechnology, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/b3f20075c3e7d7b1970f6e0bb32f86dcdd6329a1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Genetics
In Pulmonary and Respiratory Medicine
Citations in the corpus
- The microenvironmental landscape of brain tumors (2017, background): “…Cancer Cell 31, March 13, 2017 suggest that these strategies may be optimally used in the recurrent setting in combination with additional therapies (Friedman et al., 2009; Kreisl et al., 2009), rather than as frontline monotherapy on newly diagnosed, untreated disease (Gilbert et al., 2014).”
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010, background): “enhancement as early as 1 to 2 days after initiation of therapy and commonly result in high radiologic response rates of 25% to 60%.(43-46)”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “High response rates and a steroid-sparing effect have been observed with the administration of bevacizumab (± irinotecan); however, the effect is frequently short-lived and may be due exclusively to changes in vascular permeability; the effect on life expectancy remains unknown [III, C] [56, 57].”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Consequently, in February 2004, the FDA approved the use of bevacizumab for the Bevacizumab monotherapy was also efficacious in recurrent glioblastoma multiforme (GBM), with response rates in 20% to 25% of patients 85,86 , resulting in FDA approval in 2009.”
- Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “Bevacizumab was associated with a radiological response (the so-called pseudo-response) in 30-40 % of the cases in single arm studies associated with irinotecan [73, 74].”